Dorothee Gramatzki1,2, James Louis Rogers1, Marian Christoph Neidert2, Caroline Hertler1,3, Emilie Le Rhun1, Patrick Roth1, Michael Weller1. 1. Department of Neurology & Brain Tumor Center, Clinical Neuroscience Center, University Hospital and University of Zurich, Switzerland. 2. Department of Neurosurgery, Clinical Neuroscience Center, University Hospital Zurich and University of Zurich, Switzerland. 3. Department of Radiation Oncology, University Hospital Zurich and University of Zurich, Switzerland.
Abstract
BACKGROUND: Antidepressant drugs have shown antitumor activity in preclinical glioblastoma studies. Antidepressant drug use, as well as its association with survival, in glioblastoma patients has not been well characterized on a population level. METHODS: Patient characteristics, including the frequency of antidepressant drug use, were assessed in a glioblastoma cohort diagnosed in a 10-year time frame between 2005 and 2014 in the Canton of Zurich, Switzerland. Cox proportional hazards regression models were applied for multivariate analysis. Kaplan-Meier survival curves were used to estimate overall survival (OS) data and the log-rank test was performed for comparisons. RESULTS: A total of 404 patients with isocitrate dehydrogenase wild-type glioblastoma were included in this study. Sixty-five patients (16.1%) took antidepressant drugs at some point during the disease course. Patients were most commonly prescribed selective serotonin reuptake inhibitors at any time (N = 46, 70.8%). Nineteen patients (29.2%) were on antidepressant drugs at the time of their tumor diagnosis. No differences were observed in OS between those patients who had taken antidepressants at some point in their disease course and those who had not (P = .356). These data were confirmed in a multivariate analysis including age, Karnofsky Performance Scale (KPS), sex, extent of resection, O6-methylguanine DNA methyltransferase (MGMT) promoter methylation status, and first-line treatment as cofounders (P = .315). Also, there was no association of use of drugs modulating voltage-dependent potassium channels (citalopram; escitalopram) with survival (P = .639). CONCLUSIONS: This signal-seeking study does not support the hypothesis that antidepressants have antitumor efficacy in glioblastoma on a population level.
BACKGROUND: Antidepressant drugs have shown antitumor activity in preclinical glioblastoma studies. Antidepressant drug use, as well as its association with survival, in glioblastoma patients has not been well characterized on a population level. METHODS: Patient characteristics, including the frequency of antidepressant drug use, were assessed in a glioblastoma cohort diagnosed in a 10-year time frame between 2005 and 2014 in the Canton of Zurich, Switzerland. Cox proportional hazards regression models were applied for multivariate analysis. Kaplan-Meier survival curves were used to estimate overall survival (OS) data and the log-rank test was performed for comparisons. RESULTS: A total of 404 patients with isocitrate dehydrogenase wild-type glioblastoma were included in this study. Sixty-five patients (16.1%) took antidepressant drugs at some point during the disease course. Patients were most commonly prescribed selective serotonin reuptake inhibitors at any time (N = 46, 70.8%). Nineteen patients (29.2%) were on antidepressant drugs at the time of their tumor diagnosis. No differences were observed in OS between those patients who had taken antidepressants at some point in their disease course and those who had not (P = .356). These data were confirmed in a multivariate analysis including age, Karnofsky Performance Scale (KPS), sex, extent of resection, O6-methylguanine DNA methyltransferase (MGMT) promoter methylation status, and first-line treatment as cofounders (P = .315). Also, there was no association of use of drugs modulating voltage-dependent potassium channels (citalopram; escitalopram) with survival (P = .639). CONCLUSIONS: This signal-seeking study does not support the hypothesis that antidepressants have antitumor efficacy in glioblastoma on a population level.
Authors: Sébastien Bonnet; Stephen L Archer; Joan Allalunis-Turner; Alois Haromy; Christian Beaulieu; Richard Thompson; Christopher T Lee; Gary D Lopaschuk; Lakshmi Puttagunta; Sandra Bonnet; Gwyneth Harry; Kyoko Hashimoto; Christopher J Porter; Miguel A Andrade; Bernard Thebaud; Evangelos D Michelakis Journal: Cancer Cell Date: 2007-01 Impact factor: 31.743
Authors: J P Steinbach; H-P Blaicher; U Herrlinger; W Wick; T Nägele; R Meyermann; M Tatagiba; M Bamberg; J Dichgans; H-O Karnath; M Weller Journal: Neurology Date: 2006-01-24 Impact factor: 9.910
Authors: L A Pardo; D Gómez-Varela; F Major; K Sansuk; R Leurs; B R Downie; L F Tietze; W Stühmer Journal: Curr Med Chem Date: 2012 Impact factor: 4.530
Authors: Michael Weller; Martin van den Bent; Jörg C Tonn; Roger Stupp; Matthias Preusser; Elizabeth Cohen-Jonathan-Moyal; Roger Henriksson; Emilie Le Rhun; Carmen Balana; Olivier Chinot; Martin Bendszus; Jaap C Reijneveld; Frederick Dhermain; Pim French; Christine Marosi; Colin Watts; Ingela Oberg; Geoffrey Pilkington; Brigitta G Baumert; Martin J B Taphoorn; Monika Hegi; Manfred Westphal; Guido Reifenberger; Riccardo Soffietti; Wolfgang Wick Journal: Lancet Oncol Date: 2017-05-05 Impact factor: 41.316
Authors: Dorothee Gramatzki; Silvia Dehler; Elisabeth Jane Rushing; Kathrin Zaugg; Silvia Hofer; Yasuhiro Yonekawa; Helmut Bertalanffy; Anton Valavanis; Dimitri Korol; Sabine Rohrmann; Miklos Pless; Joachim Oberle; Patrick Roth; Hiroko Ohgaki; Michael Weller Journal: Cancer Date: 2016-04-18 Impact factor: 6.860
Authors: David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison Journal: Acta Neuropathol Date: 2016-05-09 Impact factor: 17.088
Authors: Han Sol Kim; Hongliang Li; Hye Won Kim; Sung Eun Shin; Mi Seon Seo; Jin Ryeol An; Kwon-Soo Ha; Eun-Taek Han; Seok-Ho Hong; Il-Whan Choi; Grace Choi; Dae-Sung Lee; Won Sun Park Journal: Korean J Physiol Pharmacol Date: 2017-06-26 Impact factor: 2.016
Authors: Erik E Rabin; Miri Kim; Andreas Mozny; Krislyn Cardoza; April C Bell; Lijie Zhai; Prashant Bommi; Kristen L Lauing; Amanda L King; Terri S Armstrong; Theresa L Walunas; Deyu Fang; Ishan Roy; John D Peipert; Erica Sieg; Xinlei Mi; Christina Amidei; Rimas V Lukas; Derek A Wainwright Journal: Brain Behav Immun Health Date: 2022-03-23